Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? (Q80316215)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

0 references

1 reference

title

Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Karumanchi SA

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Epstein FH

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

959-961

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495934%20AND%20SRC:MED&resulttype=core&format=json

Preeclampsia: a renal perspective

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Latest advances in understanding preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Circulating angiogenic factors and the risk of preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Circulating angiogenic proteins in trisomy 13

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Reversible posterior leukoencephalopathy syndrome and bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

A reversible posterior leukoencephalopathy syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Pre-eclampsia in pregnancy and subsequent risk for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021

Soluble endoglin contributes to the pathogenesis of preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002281

7 January 2021